Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2010

View Archived Issues

NVP-LDE-225: a newly discovered therapeutic candidate for Gorlin's syndrome / News in Context

Nerviano Medical Sciences discloses new pim-1 and pim-2 kinase inhibitors

Phenomix identifies new NS3 NS4A protease inhibitors for HCV infection

Merck Frosst claims new prostanoid DP2 receptor antagonists

Allergan describes novel alpha2B-adrenoceptor antagonists

Merck Frosst discloses new prostanoid EP4 receptor antagonists

Phase III data presented on sodium oxybate in fibromyalgia

Phase II/III data on tafamidis meglumine in TTR-type familial amyloid polyneuropathy

Fab-001 potently active against multiple staphylococcal strains in preclinical study

Ark begins phase I/IIa trial of high-dose VEGF-D in peripheral vascular disease

Phase Ib safety/efficacy data disclosed on SD-101 in treatment-naive hepatitis C

BioMarin launches Firdapse in Europe for Lambert-Eaton myasthenic syndrome

Shionogi and Eli Lilly launch Cymbalta in Japan for depression and depressive symptoms

Javelin terminates merger agreement with Myriad

CSL Behring receives FDA approval to extend shelf life of Privigen

Hygeia Therapeutics to advance development of topical hormone receptor modulators

Meda launches EpiCept's Ceplene in the U.K.

FDA approves BioAlliance's Oravig for oropharyngeal candidiasis

Protein Potential receives NIAID grant to develop malaria vaccine

AMRI and Navigen enter into research collaboration

Takeda obtains five NDA approvals in Japan

Gilead halts phase II trial of GS-9450 in chronic hepatitis C

GSK receives conditional marketing approval for Arzerra in Europe

Dexmedetomidine meets phase III primary endpoint in sedation of ICU patients

Prana Biotechnology set for phase IIb PBT-2 trial in Alzheimer's disease

MTD of EMD-534085 established in phase I trial in advanced solid tumors and lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...